Prescription Drugs in the Pandemic, Year 2: Pricing Rx and Going Direct-to-Consumer

There is one health care public policy issue that unites U.S. voters across political party: that is the consumer-facing costs of prescription drugs.
With the price of medicines in politicians’ and health citizens’ cross-hairs, the pharmaceutical and biotech industries have responded in many ways to the Rx pricing critiques from consumers (via, for example, Consumer Reports /Consumers Union and AARP), hospitals (through the American Hospital Association), and insurance companies (from AHIP, America’s Health Insurance Plans).
The latest poll from the University of Chicago/Harris Public Policy and the Associate Press-NORC Center for Public Affairs Research quantifies the issue …

Read the source article at MaxiHealth Blog
2021-08-17 09:14:00